Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse

Drug Metabolism and Disposition

Volumn 36, Issue 8, 2008, Pages 1476-1484

  Giri, Nagdeep ^a   Shaik, Naveed ^a   Pan, Guoyu ^a   Terasaki, Tetsuya ^b   Mukai, Chisato ^c   Kitagaki, Shinji ^c   Miyakoshi, Naoki ^c   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b TOHOKU UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 ISOBUTYL 9 METHOXY 1,4 DIOXO 1,2,3,4,6,7,12,12A OCTAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOL 3 YL)PROPIONIC ACID TERT BUTYL ESTER; ABACAVIR; BREAST CANCER RESISTANCE PROTEIN; DIDANOSINE; ELACRIDAR; FUMITREMORGIN C; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; KO 143; LAMIVUDINE; PLURONIC P85; POLOXAMER; PROBENECID; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE; ZOSUQUIDAR;

ACTIVE TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BINDING; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; GENE DELETION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIDEOXYNUCLEOSIDES; MICE; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE INHIBITORS; TISSUE DISTRIBUTION; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 47949129693     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020974     Document Type: Article

References (36)

1. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16:303-309.
2. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, and Elmquist WF (2001) Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 296:551-557.
3. Bihorel S, Camenisch G, Lemaire M, and Scherrmann JM (2007) Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 24:1720-1728.
4. Cooray HC, Blackmore CG, Maskell L, and Barrand MA (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13:2059-2063.
5. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, and Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287.
6. Dai H, Marbach P, Lemaire M, Hayes M, and Elmquist WF (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085-1092.
7. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, and van Tellingen O (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13:6440-6449.
8. Dieterich DT (2006) Disease management - constructing optimal NRTI-based combinations: past, present, and future. MedGenMed 8:16.
9. Doshi KJ, Gallo JM, Boudinot FD, Schinazi RF, and Chu CK (1989) Comparative pharmacokinetics of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′,3′-dideoxyuridine (AZddU) in mice. Drug Metab Dispos 17:590-594.
10. Doyle LA and Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358.
11. Enokizono J, Kusuhara H, Ose A, Schinkel AH, and Sugiyama Y (2008) Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 36:995-1002.
12. Enokizono J, Kusuhara H, and Sugiyama Y (2007) Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol 72:967-975.
13. Gibbs JE, and Thomas SA (2002) The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem 80:392-404.
14. Gupta A, Zhang Y, Unadkat JD, and Mao Q (2004) HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 310:334-341.
15. Hori S, Ohtsuki S, Tachikawa M, Kimura N, Kondo T, Watanabe M, Nakashima E, and Terasaki T (2004) Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem 90:526-536.
16. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99:15649-15654.
17. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
18. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res, in press.
19. Krishnamurthy P and Schuetz JD (2006) Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46:381-410.
20. Kvackajova-Kisucka J, Barancik M, and Breier A (2001) Drug transporters and their role in multidrug resistance of neoplastic cells. Gen Physiol Biophys 20:215-237.
21. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, and Sugiyama Y (2005) Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 312:44-52.
22. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
23. Nedelman JR and Jia X (1998) An extension of Satterthwaite's approximation applied to pharmacokinetics. J Biopharm Stat 8:317-328.
24. Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP, and Keppler D (2004) Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129:349-360.
25. Ohtsuki S and Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24:1745-1758.
26. Pan G, Giri N, and Elmquist WF (2007) Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos 35:1165-1173.
27. Sawchuk RJ and Yang Z (1999) Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev 39:5-31.
28. Shaik N, Giri N, Pan G, and Elmquist WF (2007) P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 35:2076-2085.
29. Takasawa K, Terasaki T, Suzuki H, and Sugiyama Y (1997) In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J Pharmacol Exp Ther 281:369-375.
30. Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Leggas M, Ejendal KF, Hrycyna CA, and Schuetz JD (2007) Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 67:6965-6972.
31. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, and Schinkel AH (2003) The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine. Cancer Res 63:6447-6452.
32. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, and Baba M (2003) Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 63:65-72.
33. Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, Sugimoto Y, Akiyama S, and Baba M (2004) Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol 68:1363-1370.
34. Wang Y, Wei Y, and Sawchuk RJ (1997) Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. J Pharm Sci 86:1484-1490.
35. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, and Efferth T (2007) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59:238-245.
36. Yuan J (1993) Estimation of variance for AUC in animal studies. J Pharm Sci 82:761-763.